NCT06441578View on ClinicalTrials.gov

A Survey of Recombinant ADAMTS13 in Participants With Congenital Thrombotic Thrombocytopenic Purpura

RecruitingOBSERVATIONAL

Enrollment

40

Participants

Timeline

Start Date

May 30, 2024

Primary Completion Date

September 30, 2032

Study Completion Date

September 30, 2032

Conditions

Thrombotic Thrombocytopenic Purpura (TTP)

Interventions

DRUG

Recombinant ADAMTS13

Recombinant ADAMTS13, Intravenous injection

Trial Locations (1)

Unknown

RECRUITING

Takeda selected site, Tokyo

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Takeda

INDUSTRY